Press release
Biosimilar Interleukins Market Size Forecasted To Achieve $20.79 Billion By 2029 With Steady Growth
Biosimilar Interleukins
What Is the Biosimilar Interleukins Market Size and Projected Growth Rate?
The biosimilar interleukins market has grown rapidly in recent years. It will increase from $3.9 billion in 2024 to $5.41 billion in 2025 at a compound annual growth rate (CAGR) of 39.0%. This growth is attributed to the rise in autoimmune diseases, greater awareness of biosimilar interleukins, enhanced government support for biosimilars, the expansion of the biosimilar market, and the increasing demand from patients.
The biosimilar interleukins market is forecast to grow exponentially, hitting $20.79 billion by 2029 with a CAGR of 40.0%. Contributing factors include expanding patient base, rising access to care, preference for personalized treatments, and less invasive options. Major trends include global collaborations, quality manufacturing, targeted immunotherapies, and technological advances in biosimilars.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3433
What Are the Major Segments in the Biosimilar Interleukins Market?
The biosimilar interleukins market covered in this report is segmented -
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp
What Are The Driving Biosimilar Interleukins Market Evolution?
Increasing cases of autoimmune disorders such as psoriasis and rheumatoid arthritis are supporting the interleukin biosimilars market growth. These diseases result from immune system malfunctions, and interleukin-targeting biologics help manage them. The National Institutes of Health reported in February 2024 that global autoimmune disease incidence and prevalence are rising annually by 19.1% and 12.5% respectively, reinforcing market demand.
Which Firms Dominate The Biosimilar Interleukins Market Segments?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
What Trends Are Driving Growth in The Biosimilar Interleukins Market?
Leading companies in the biosimilar interleukins market are developing new products, such as Tofidence (tocilizumab-bavi), to boost profitability. Tofidence, a monoclonal antibody targeting interleukin-6 receptors, is used to treat various inflammatory autoimmune disorders. In September 2023, Biogen received FDA approval for Tofidence as the first biosimilar to Genentech's Actemra. Tofidence is administered through intravenous infusion and is approved for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report
Which Is The Largest Region In The Biosimilar Interleukins Market?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Biosimilar Interleukins Market?
2. What is the CAGR expected in the Biosimilar Interleukins Market?
3. What Are the Key Innovations Transforming the Biosimilar Interleukins Industry?
4. Which Region Is Leading the Biosimilar Interleukins Market?
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Interleukins Market Size Forecasted To Achieve $20.79 Billion By 2029 With Steady Growth here
News-ID: 4056777 • Views: …
More Releases from The Business Research Company
Future of the End Load Cartoning Machines Market: Trends, Innovations, and Key F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
End Load Cartoning Machines Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a robust growth in the market size of end load cartoning machines. It is projected to rise from $2.23 billion in 2024 to $2.39 billion in 2025, with…
Automatic Effluent Samplers Market Expansion Continues, with Forecast Valuation …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Automatic Effluent Samplers Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for automatic effluent samplers has witnessed robust growth in the last few years. It is predicted to expand from $1.66 billion in 2024 to $1.83 billion by 2025, demonstrating an impressive compound…
Top Market Shifts Transforming the Nanomachines Market Landscape: Key Insights
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Nanomachines Market Through 2025?
The market for nanomachines has undergone swift expansion in the past few years. The market's magnitude is projected to increase from $22.12 billion in 2024 to $25.67 billion in 2025, recording a compound annual growth rate (CAGR) of…
Growing Demand For Precision Manufacturing Drives Market Growth With A Rise In A …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Hot Runner Temperature Controller Industry Market Size Be by 2025?
There has been consistent growth in the hot runner temperature controller market size over the past few years. The market is forecasted to rise from a valuation of $0.74 billion in 2024 to $0.77 billion in…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
